TSE:ONCOncolytics Biotech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oncolytics Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$2.53 +0.01 (+0.40 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's RangeC$2.51Now: C$2.53▼C$2.5550-Day RangeC$2.52MA: C$2.97▼C$3.8352-Week RangeC$0.48Now: C$2.53▼C$7.84Volume18,867 shsAverage Volume346,018 shsMarket CapitalizationC$102.44 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$6.00, Oncolytics Biotech has a potential upside of 137.2% from its current price of C$2.53.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 1 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesOncolytics Biotech has received 177 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOncolytics Biotech has received 127 “underperform” votes. (Add your “underperform” vote.)Community SentimentOncolytics Biotech has received 58.22% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote “Outperform” if you believe ONC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOncolytics Biotech does not currently pay a dividend.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Oncolytics Biotech are expected to grow in the coming year, from C($0.36) to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 4.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.41 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:ONC Previous Symbol CUSIPN/A CIKN/A Webwww.oncolyticsbiotech.com Phone+1-403-6707380Debt Debt-to-Equity Ratio1.87 Current Ratio7.89 Quick Ratio7.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.78 per share Price / Cash Flow3.24 Book ValueC$0.62 per share Price / Book4.08Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares40,492,000Market CapC$102.44 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable TSX:ONC Rates by TradingView Receive ONC News and Ratings via Email Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Oncolytics Biotech (TSE:ONC) Frequently Asked Questions How has Oncolytics Biotech's stock been impacted by COVID-19 (Coronavirus)? Oncolytics Biotech's stock was trading at C$2.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ONC shares have increased by 6.8% and is now trading at C$2.53. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Oncolytics Biotech? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Oncolytics Biotech. When is Oncolytics Biotech's next earnings date? Oncolytics Biotech is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Oncolytics Biotech. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech, Inc. (TSE:ONC) posted its earnings results on Friday, May, 8th. The company reported ($0.20) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.01. View Oncolytics Biotech's earnings history. What price target have analysts set for ONC? 2 analysts have issued 1 year target prices for Oncolytics Biotech's stock. Their forecasts range from C$6.00 to C$6.00. On average, they anticipate Oncolytics Biotech's stock price to reach C$6.00 in the next year. This suggests a possible upside of 137.2% from the stock's current price. View analysts' price targets for Oncolytics Biotech. Has Oncolytics Biotech been receiving favorable news coverage? News stories about ONC stock have been trending somewhat negative on Saturday, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Oncolytics Biotech earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news about Oncolytics Biotech. Who are some of Oncolytics Biotech's key competitors? Some companies that are related to Oncolytics Biotech include Silence Therapeutics (SLN), Neptune Wellness Solutions (NEPT), TELIX Pharmaceutical (TLX), Starpharma (SPL), ProMetic Life Sciences (PLI), Pfenex (PFNX), IMV (IMV), Emblem (EMC), Medicenna Therapeutics (MDNA), Ergomed (ERGO), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), Exicure (XCUR), OncoCyte (OCX) and Theratechnologies (TH). View all competitors. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), Oncolytics Biotech (ONCYF), Resverlogix (RVX), Encana (ECA), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), First Majestic Silver (FR) and Husky Energy (HUSKF). Who are Oncolytics Biotech's key executives? Oncolytics Biotech's management team includes the following people: Dr. Matthew C. Coffey, Pres, CEO & DirectorMr. Kirk J. Look, Chief Financial OfficerMr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 52)Mr. Michael Moore, VP of Investor Relations & Corp. CommunicationsDr. Rita Laeufle, Chief Medical Officer What is Oncolytics Biotech's stock symbol? Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC." How do I buy shares of Oncolytics Biotech? Shares of ONC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Oncolytics Biotech's stock price today? One share of ONC stock can currently be purchased for approximately C$2.53. How big of a company is Oncolytics Biotech? Oncolytics Biotech has a market capitalization of C$102.44 million. What is Oncolytics Biotech's official website? The official website for Oncolytics Biotech is www.oncolyticsbiotech.com. How can I contact Oncolytics Biotech? Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380. This page was last updated on 7/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
